Provided by Tiger Trade Technology Pte. Ltd.

Medpace

459.77
+8.571.90%
Volume:23.10K
Turnover:10.62M
Market Cap:13.05B
PE:30.09
High:460.84
Open:460.84
Low:448.29
Close:451.20
52wk High:628.92
52wk Low:250.05
Shares:28.38M
Float Shares:22.22M
Volume Ratio:0.58
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.28
EPS(LYR):15.28
ROE:70.23%
ROA:16.40%
PB:28.42
PE(LYR):30.09

Loading ...

Stock Track | Medpace Plummets 10.72% Intraday on Profit Margin Concerns and Guidance Disappointment

Stock Track
·
Feb 10

Medpace says cancellations ‘widespread’ in Q4

TIPRANKS
·
Feb 10

Stock Track | Medpace Plunges 5.16% in Pre-market on Profit Margin Concerns Despite Earnings Beat

Stock Track
·
Feb 10

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Medpace Holdings (MEDP)

TIPRANKS
·
Feb 10

Stock Track | Medpace Plunges 5.35% on Profit Margin Concerns Despite Earnings Beat

Stock Track
·
Feb 10

Stock Track | Medpace Plunges 5.15% After Hours Despite Earnings Beat as Margins Contract

Stock Track
·
Feb 10

Medpace reports Q4 EPS $4.67, consensus $4.23

TIPRANKS
·
Feb 10

GUIDANCE: (MEDP) Medpace Expects 2026 Revenue Range $2.755B-$2.855B, vs. FactSet Est of $2.81B

MT Newswires Live
·
Feb 10

Earnings Flash (MEDP) Medpace Posts Q4 EPS $4.67, vs. FactSet Est of $4.19

MT Newswires Live
·
Feb 10

Medpace reports Q4 revenue of USD 708.5 million, up 32%

Reuters
·
Feb 10

Medpace Outlook FY EPS USD 16.68-17.5

THOMSON REUTERS
·
Feb 10

U.S. Earnings Preview: After Market Close Feb. 9

Dow Jones
·
Feb 10

Earnings Preview: Medpace Q4 revenue is expected to increase by 28.91%, and institutional views are predominantly positive

Earnings Agent
·
Feb 02

Is It Too Late To Consider Medpace (MEDP) After Its Strong Multi Year Share Price Run

Simply Wall St.
·
Feb 01

Medpace Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results

Reuters
·
Jan 06

Medpace (MEDP): Assessing Valuation After a Strong Multi‑Year Share Price Run

Simply Wall St.
·
Dec 25, 2025

Medpace Holdings Is Maintained at Underweight by Barclays

Dow Jones
·
Dec 16, 2025

Is Medpace Still Attractive After Its Huge Multi Year Share Price Surge in 2025

Simply Wall St.
·
Dec 12, 2025

Medpace CEO August J. Troendle Reports Sale of Common Shares

Reuters
·
Dec 02, 2025

Medpace Exec. VP Susan E. Burwig Reports Sale of Common Shares

Reuters
·
Nov 27, 2025